Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics ( (CLDI) ) just unveiled an update.
On August 29, 2025, Calidi Biotherapeutics, Inc. released an updated presentation on its website. The company clarified that the information provided is not considered material and is not subject to liabilities under the Securities Exchange Act of 1934.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Average Trading Volume: 1,560,286
Technical Sentiment Signal: Sell
Current Market Cap: $8.38M
For detailed information about CLDI stock, go to TipRanks’ Stock Analysis page.